ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Natural Bladder Control, Go Less and Live More

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Top Vitamin and Mineral Deficiencies — Are You at Risk?

How Pomegranate May Protect Against Cancer

Omega Fix for Obesity: How the Right Fats Fight Fat

Trimming the spare tire: Canola oil may cut belly fat

The Onion: Cancer Fighter and Food Preserver

Fighting Heartburn and Gerd Naturally – And Safely!

Probiotics improve cognition in Alzheimer's patients

Safely Reduce a Common Cause of Stomach Distress

 
Print Page
Email Article

Another look at esreboxetine: 4th Rx alternative for fibromyalgia?

  [ 52 votes ]   [ Discuss This Article ]
www.ProHealth.com • July 26, 2012


A paper published in the July 2012 issue of Arthritis & Rheumatism...
Suggests a renewed investment interest by Pfizer Inc. in trials of its investigational drug esreboxetine as an FM therapy. (See “Safety and efficacy of esreboxetine in patients with Fibromyalgia: A 14-week, randomized, double-blind, placebo-controlled, multicenter clinical trial,” by University of Cincinnati fibromyalgia researcher Lesley M Arnold, MD, and a team at the UK-based Pfizer Global Research and Development organization.) 

For specifics not offered in the abstract of this fee-based paper...
See MedPageToday's physician CME report (“Novel Drug Helped in Fibromyalgia”).

By way of background, in Feb 2009...
Pfizer announced that they were discontinuing phase 3 trials of esreboxetine after their review of existing phase 2 trial data indicated the drug was unlikely to “provide meaningful benefit to patients beyond” other fibromyalgia Rx therapies that were already FDA approved (including Pfizer’s Lyrica, aka pregabalin). The average pain score improvement in trials of the drugs had been in the neighborhood of 30% or more, about what the new Arnold, et al. paper reports.

Now, however, at least two factors have entered the mix:

• The big three FDA approved fibromyalgia drugs will be coming off patent starting Oct 2013 with Lyrica, opening this huge multi-billion-dollar market to competition from generally lower price generics. For example, on July 5, the FDA approved marketing of a generic pregabalin product by Lupin Pharmaceuticals. At the same time, industry analysts predict "huge market opportunities" for pharmaceutical companies owing to increased FM awareness, diagnosis rates, and market penetration. 

• And second, it is suggested that the new research reflects physician/patient experience over the past few years demonstrating that responses to/side effects of the approved drugs – and to different combinations of those drugs – differ, sometimes significantly, from patient to patient. A factor that may overcome regulatory preference for a focus on drugs to treat unmet needs.

Currently, for example, a trial at the University of Utah is recruiting fibro patients to determine if differences in blood biomarkers can be linked to different responses to Lyrica (pregabalin) therapy.

Each of the approved drugs - and reboxetine - involves a different mechanism of action (albeit sometimes not entirely understood).
 
• Unlike the three currently approved drugs, esreboxetine is “a highly-selective norepinephrine reuptake inhibitor”: that is, it concentrates only norepinephrine in the brain.

• Savella (milnacipran) and Cymbalta (duloxetine) concentrate both serotonin and norepinephrine, though by different means.

• Lyrica (pregabalin) is said to decrease the release of the neurotransmitters substance P and glutamate, and “restore” release of norepinephrine.

So overall it seems fibromyalgia and neuropathic pain patients and their physicians can expect to see continued FM drug research, by Dr. Arnold at the University of Cincinnati and others.




Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Ultra EPA  - Fish Oil Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Complete and Natural Menopause Relief Complete and Natural Menopause Relief
How Glutathione Can Save Your Life How Glutathione Can Save Your Life
Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt
The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol
Fighting Fatigue with Ground-breaking French Oak Wood Extract Fighting Fatigue with Ground-breaking French Oak Wood Extract

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map